147 results on '"Vavricka, Stephan R."'
Search Results
2. The Genetics of Inflammatory Bowel Disease.
- Author
-
El Hadad J, Schreiner P, Vavricka SR, and Greuter T
- Subjects
- Humans, Genome-Wide Association Study, Azathioprine therapeutic use, Inflammatory Bowel Diseases diagnosis, Inflammatory Bowel Diseases genetics, Colitis, Ulcerative drug therapy, Colitis, Ulcerative genetics, Colitis, Ulcerative diagnosis, Crohn Disease diagnosis, Crohn Disease drug therapy, Crohn Disease genetics
- Abstract
The genetic background of inflammatory bowel disease, both Crohn's disease and ulcerative colitis, has been known for more than 2 decades. In the last 20 years, genome-wide association studies have dramatically increased our knowledge on the genetics of inflammatory bowel disease with more than 200 risk genes having been identified. Paralleling this increasing knowledge, the armamentarium of inflammatory bowel disease medications has been growing constantly. With more available therapeutic options, treatment decisions become more complex, with still many patients experiencing a debilitating disease course and a loss of response to treatment over time. With a better understanding of the disease, more effective personalized treatment strategies are looming on the horizon. Genotyping has long been considered a strategy for treatment decisions, such as the detection of thiopurine S-methyltransferase and nudix hydrolase 15 polymorphisms before the initiation of azathioprine. However, although many risk genes have been identified in inflammatory bowel disease, a substantial impact of genetic risk assessment on therapeutic strategies and disease outcome is still missing. In this review, we discuss the genetic background of inflammatory bowel disease, with a particular focus on the latest advances in the field and their potential impact on management decisions., (© 2023. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
3. [Extraintestinal manifestations in inflammatory bowel disease].
- Author
-
Vavricka SR
- Subjects
- Humans, Quality of Life, Inflammatory Bowel Diseases complications, Inflammatory Bowel Diseases diagnosis, Inflammatory Bowel Diseases therapy, Crohn Disease complications, Crohn Disease diagnosis, Crohn Disease therapy, Colitis, Ulcerative complications, Colitis, Ulcerative diagnosis, Colitis, Ulcerative drug therapy
- Abstract
Introduction: Chronic inflammatory bowel diseases (IBD) are inflammatory gastrointestinal disorders that are not limited to the gastrointestinal tract. Many different organ systems may be involved, which makes IBD a systemic disease. The most common extraintestinal manifestations (EIM) include musculoskeletal, ophthalmological, dermatological, and hepato-biliary disorders. EIM considerably contribute to the morbidity of patients with IBD, and they limit quality of life of affected patients. Due to the diversity of the organ systems involved, care should be provided by an interdisciplinary team. Early detection of EIM allows targeted therapy and reduces overall morbidity. Of importance is the fact that EIM can occur in up to 25% of all IBD patients before the onset of the first Crohn's episode or ulcerative colitis. Therefore, all doctors, especially dermatologists, ophthalmologists and rheumatologists should be aware of this possible association between EIM and the simultaneous occurrence of intestinal symptoms., Competing Interests: Der Autor hat keine Interessenkonflikte., (© 2023 Aerzteverlag medinfo AG.)
- Published
- 2023
4. Impact of Vedolizumab on Extraintestinal Manifestations in Inflammatory Bowel Disease: Results From a Descriptive, Retrospective, Real-world Study.
- Author
-
Kopylov U, Burisch J, Ben-Horin S, Braegger F, Fernández-Nistal A, Lara N, Heinrich HS, and Vavricka SR
- Subjects
- Adult, Humans, Retrospective Studies, Arthralgia, Inflammatory Bowel Diseases, Crohn Disease, Colitis, Ulcerative
- Abstract
Background: Patients with inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis, may develop extraintestinal manifestations (EIMs). The EMOTIVE study aimed to analyze the effect of vedolizumab on EIMs in a real-world cohort of patients with IBD., Methods: This multicenter, descriptive, retrospective study was conducted in Belgium, Denmark, Israel, the Netherlands, and Switzerland in adults with moderately to severely active IBD and concurrent active EIMs at vedolizumab initiation (index date), with a ≥6-month follow-up after the index date. The primary endpoint was resolution of all EIMs within 6 months of vedolizumab initiation., Results: In 99 eligible patients, the most frequent EIMs were arthralgia (69.7%), peripheral spondyloarthritis (21.2%), and axial spondyloarthritis (10.1%). Within 6 and 12 months of vedolizumab initiation, 19.2% and 25.3% of patients reported resolution of all EIMs, while 36.5% and 49.5% of all EIMs were reported to be improved (combination of resolution and partial response), respectively. Vedolizumab treatment persistence at 12 months was 82.8%. Adverse events were reported in 18.2% of patients, with the most frequent being arthralgia (4.0%)., Conclusions: This real-world study showed resolution of all EIMs in up to one-fourth of patients with IBD and improvement in up to half of EIMs within 12 months of vedolizumab treatment. Overall, vedolizumab was effective on EIMs in patients with IBD and showed a good safety profile., (© 2023 Crohn’s & Colitis Foundation. Published by Oxford University Press on behalf of Crohn’s & Colitis Foundation.)
- Published
- 2023
- Full Text
- View/download PDF
5. Spondyloarthritis with inflammatory bowel disease: the latest on biologic and targeted therapies.
- Author
-
Cozzi G, Scagnellato L, Lorenzin M, Savarino E, Zingone F, Ometto F, Favero M, Doria A, Vavricka SR, and Ramonda R
- Subjects
- Humans, Quality of Life, Tumor Necrosis Factor Inhibitors therapeutic use, Spondylarthritis complications, Inflammatory Bowel Diseases complications, Biological Products therapeutic use
- Abstract
Spondyloarthritis (SpA) encompasses a heterogeneous group of chronic inflammatory diseases that can affect both axial and peripheral joints, tendons and entheses. Among the extra-articular manifestations, inflammatory bowel disease (IBD) is associated with considerable morbidity and effects on quality of life. In everyday clinical practice, treatment of these conditions requires a close collaboration between gastroenterologists and rheumatologists to enable early detection of joint and intestinal manifestations during follow-up and to choose the most effective therapeutic regimen, implementing precision medicine for each patient's subtype of SpA and IBD. The biggest issue in this field is the dearth of drugs that are approved for both diseases, as only TNF inhibitors are currently approved for the treatment of full-spectrum SpA-IBD. Janus tyrosine kinase inhibitors are among the most promising drugs for the treatment of peripheral and axial SpA, as well as for intestinal manifestations. Other therapies such as inhibitors of IL-23 and IL-17, phosphodiesterase 4 inhibitor, α4β7 integrin blockers and faecal microbiota transplantation seem to only be able to control some disease domains, or require further studies. Given the growing interest in the development of novel drugs to treat both conditions, it is important to understand the current state of the art and the unmet needs in the management of SpA-IBD., (© 2023. Springer Nature Limited.)
- Published
- 2023
- Full Text
- View/download PDF
6. Malignancy rates in Crohn's disease patients with perianal fistula: A German retrospective cohort study.
- Author
-
Podmore B, Beier D, Burisch J, Genestin E, Haeckl D, Nagel O, Qizilbash N, Schwartz DA, Vavricka SR, Bennett D, and Dignass A
- Subjects
- Humans, Retrospective Studies, Crohn Disease complications, Crohn Disease diagnosis, Crohn Disease epidemiology, Inflammatory Bowel Diseases complications, Neoplasms, Rectal Fistula epidemiology, Rectal Fistula etiology
- Abstract
Background: Patients with inflammatory bowel disease are at increased risk of colorectal and extra-intestinal cancer. However, the overall cancer risk in patients with Crohn's disease (CD) with perianal fistulas (PF) (CPF) and those with CD without PF (non-PF CD) is unclear., Objective: To describe the prevalence and incidence of cancer in patients with CPF and non-PF CD, and to estimate incidence rate ratio (IRR) of cancer between CPF and non-PF CD groups., Methods: A retrospective cohort study was conducted using the German InGef (Institute for Applied Health Research Berlin) research database. Patients with a CD record and PF from 1 January 2013 to 31 December 2014 were identified and followed up from 1 January 2015 until the first occurrence of cancer, end of health insurance contributing data, death, or end of study period (31 December 2020). Prevalence of any type of cancer including patients with CD diagnosed with cancer in the selection period and incidence of cancer excluding patients with CD diagnosed with cancer in the selection period were calculated., Results: In total, 10,208 patients with CD were identified. Of 824 patients with CPF (8.1%), 67 had had a malignancy (6-year period crude malignancy prevalence 8.13% [95% confidence interval (CI) 6.36%-10.21%]), which was lower than patients with non-PF CD (19.8% [95% CI 19%-20.6%]). Incidence (per 100,000 person-years) in patients with CPF was 1184 (95% CI 879-1561) and in non-PF CD was 2365 (95% CI 2219-2519). There was no significant difference in the adjusted IRR of cancer for the CPF group compared with the non-PF CD group (0.83 [95% CI 0.62-1.10]; p = 0.219)., Conclusion: There was no significant difference in the incidence of any cancer in patients with CPF compared with non-PF CD. However, patients with CPF had a higher numerical risk of cancer than the general German population., (© 2023 Takeda Pharmaceuticals and The Authors. United European Gastroenterology Journal published by Wiley Periodicals LLC on behalf of United European Gastroenterology.)
- Published
- 2023
- Full Text
- View/download PDF
7. ECCO Guidelines on Inflammatory Bowel Disease and Malignancies.
- Author
-
Gordon H, Biancone L, Fiorino G, Katsanos KH, Kopylov U, Al Sulais E, Axelrad JE, Balendran K, Burisch J, de Ridder L, Derikx L, Ellul P, Greuter T, Iacucci M, Di Jiang C, Kapizioni C, Karmiris K, Kirchgesner J, Laharie D, Lobatón T, Molnár T, Noor NM, Rao R, Saibeni S, Scharl M, Vavricka SR, and Raine T
- Subjects
- Humans, Inflammatory Bowel Diseases complications, Inflammatory Bowel Diseases diagnosis, Inflammatory Bowel Diseases therapy, Crohn Disease, Neoplasms diagnosis, Neoplasms therapy
- Published
- 2023
- Full Text
- View/download PDF
8. Pneumocystis jirovecii Pneumonia in Patients with Inflammatory Bowel Disease-a Case Series.
- Author
-
Vieujean S, Moens A, Hassid D, Rothfuss K, Savarino EV, Vavricka SR, Reenaers C, Jacobsen BA, Allez M, Ferrante M, and Rahier JF
- Subjects
- Humans, Adult, Middle Aged, Aged, Retrospective Studies, Transplantation, Autologous adverse effects, Immunosuppressive Agents adverse effects, Pneumonia, Pneumocystis diagnosis, Pneumonia, Pneumocystis etiology, Pneumonia, Pneumocystis drug therapy, Hematopoietic Stem Cell Transplantation adverse effects, Pneumocystis carinii, Inflammatory Bowel Diseases drug therapy, Crohn Disease drug therapy
- Abstract
Background and Aim: Pneumocystis jirovecii pneumonia [PJP] is a very rare, potentially life-threatening pulmonary fungal infection that occurs in immunocompromised individuals including patients with inflammatory bowel disease [IBD]. Our aim was to describe immunosuppressive treatment exposure as well as the outcome in IBD patients with PJP., Methods: PJP cases were retrospectively collected through the COllaborative Network For Exceptionally Rare case reports of the European Crohn's and Colitis Organisation. Clinical data were provided through a case report form., Results: In all, 18 PJP episodes were reported in 17 IBD patients [10 ulcerative colitis and seven Crohn's disease]. The median age at PJP diagnosis was 55 years (interquartile range [IQR], 40-68 years]. Two PJP [11.1%] occurred in patients on triple immunosuppression, 10 patients [55.6%] had double immunosuppressive treatment, four patients [22.2%] had monotherapy and two PJP occurred in absence of immunosuppressive treatment [one in a human immunodeficiency virus patient and one in a patient with a history of autologous stem cell transplantation]. Immunosuppressive therapies included steroids [n = 12], thiopurines [n = 10], infliximab [n = 4], ciclosporin [n = 2], methotrexate [n = 1], and tacrolimus [n = 1]. None of the patients diagnosed with PJP had received prophylaxis. All patients were treated by trimethoprim/sulphamethoxazole or atovaquone and an intensive care unit [ICU] stay was required in seven cases. Two patients [aged 71 and 32 years] died, and one patient had a recurrent episode 16 months after initial treatment. Evolution was favourable for the others., Conclusion: This case series reporting potentially fatal PJP highlights the need for adjusted prophylactic therapy in patients with IBD on immunosuppressive therapy., (© The Author(s) 2022. Published by Oxford University Press on behalf of European Crohn’s and Colitis Organisation. All rights reserved. For permissions, please email: journals.permissions@oup.com.)
- Published
- 2023
- Full Text
- View/download PDF
9. Alcohol and cannabis consumption in patients with inflammatory bowel disease: prevalence, pattern of consumption and impact on the disease.
- Author
-
Martinho-Grueber M, Kapoglou I, Bravo F, Sarraj R, Benz E, Restellini S, Biedermann L, Rogler G, Vavricka SR, Schoepfer A, Maillard MH, Michetti P, Brunner F, Clair C, Barry MP, Pittet V, von Känel R, and Juillerat P
- Subjects
- Humans, Male, Prevalence, Cohort Studies, Alcohol Drinking adverse effects, Alcohol Drinking epidemiology, Ethanol, Chronic Disease, Cannabis, Inflammatory Bowel Diseases epidemiology
- Abstract
Objectives of the Study: There is little guidance regarding the impact of alcohol and cannabis on the clinical course of inflammatory bowel disease. The aim of this study was to assess the prevalence, sociodemographic characteristics and impact of alcohol and cannabis use on the clinical course of the disease., Methods: We performed an analysis of prospectively collected data within the Swiss Inflammatory Bowel Disease Cohort Study with yearly follow-ups and substance-specific questionnaires. We analyzed the prevalence of use, the profile of users at risk for addiction and the impact of alcohol and cannabis on the course of the disease., Results: We collected data of 2828 patients included between 2006 and 2018 and analyzed it according to their completion of specific surveys on alcohol and cannabis use. The prevalence of patient-reported active use was 41.3% for alcohol and 6% for cannabis. Heavy drinkers were over-represented among retired, married smokers receiving mostly aminosalicylates and less immunosuppression. In ulcerative colitis patients, low-to-moderate drinking was associated with less extensive disease. Cannabis users were often students with ileal Crohn's disease., Conclusion: A significant proportion of patients with inflammatory bowel disease consume alcohol or cannabis. Heavy alcohol consumption is most likely in male smokers >50 years, whereas young men with ileal disease rather use cannabis., (Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc.)
- Published
- 2023
- Full Text
- View/download PDF
10. Emerging treatment options for extraintestinal manifestations in IBD.
- Author
-
Greuter T, Rieder F, Kucharzik T, Peyrin-Biroulet L, Schoepfer AM, Rubin DT, and Vavricka SR
- Subjects
- Antibodies, Monoclonal therapeutic use, Humans, Tumor Necrosis Factor-alpha antagonists & inhibitors, Biological Therapy methods, Inflammatory Bowel Diseases pathology, Inflammatory Bowel Diseases therapy
- Abstract
Extraintestinal manifestations (EIMs) are frequently observed in IBDs and contribute considerably to morbidity and mortality. They have long been considered a difficult to treat entity due to limited therapy options, but the increasing use of anti-tumour necrosis factors has dramatically changed the therapeutic approach to EIM in recent years. Newly emerging therapies such as JAK inhibitors and anti-interleukin 12/23 will further shape the available armamentarium. Clinicians dealing with EIMs in everyday IBD practice may be puzzled by the numerous available biological agents and small molecules, their efficacy for EIMs and their potential off-label indications. Current guidelines on EIMs in IBD do not include treatment algorithms to help practitioners in the treatment decision-making process. Herein, we summarise knowledge on emerging biological treatment options and small molecules for EIMs, highlight current research gaps, provide therapeutic algorithms for EIM management and shed light on future strategies in the context of IBD-related EIMs., Competing Interests: Competing interests: TG has a consulting contract with Sanofi-Aventis, received a travel grant from Falk Pharma and Vifor, and an unrestricted research grant from Novartis. SRV received consultant fees and unrestricted research grants from Abbott, Celtrion, Ferring, MSD, Pfizer, Sanofi-Aventis, Takeda, Tillots, UCB, Vifor and Falk Pharma. FR has consulted with Allergan, AbbVie, Boehringer-Ingelheim, Celgene, Helmsley, Jannsen, Pliant, Receptos, RedX, Roche, Samsung, Takeda, Thetis, UCB and received research grants from Celgene, Pliant and UCB. TK received consultant fees and speaker honoraria from Abbott, Amgen, Biogen, Celtrion, Falk Pharma, Janssen, MSD, Takeda and UCB. LP-B reports personal fees from Merck, Abbvie, Janssen, Ferring, Tillots, Celltrion, Takeda, Pfizer, Amgen, Biogen, Samsung Bioepis, Genentech, Vifor, Pharmacosmos, Biogaran, Boerhinger-Ingelheim, Lilly, Index Pharmaceuticals, Sandoz, Celgene, Alma, Sterna, Nestlé and Enterome. AMS received consulting and/or speaker fees from Abbvie, Adare, Dr Falk Pharma, MSD, UCB, Pfizer, Takeda, Vifor, Receptos, Regeneron and received research grants Adare, Dr Falk Pharma, Receptos and Regeneron. No company representative was involved in conception, writing or financing of this study., (© Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.)
- Published
- 2021
- Full Text
- View/download PDF
11. Abdominal pain in patients with inflammatory bowel disease: association with single-nucleotide polymorphisms prevalent in irritable bowel syndrome and clinical management.
- Author
-
Ledergerber M, Lang BM, Heinrich H, Biedermann L, Begré S, Zeitz J, Krupka N, Rickenbacher A, Turina M, Greuter T, Schreiner P, Roth R, Siebenhüner A, Vavricka SR, Rogler G, Beerenwinkel N, and Misselwitz B
- Subjects
- Humans, Abdominal Pain genetics, Cohort Studies, Polymorphism, Single Nucleotide, Colitis, Ulcerative complications, Colitis, Ulcerative genetics, Inflammatory Bowel Diseases complications, Inflammatory Bowel Diseases genetics, Irritable Bowel Syndrome complications, Irritable Bowel Syndrome genetics
- Abstract
Background: Abdominal pain is a frequent symptom in patients with inflammatory bowel disease (IBD) including Crohn's disease (CD) and ulcerative colitis (UC). Pain can result from ongoing inflammation or functional disorders imitating irritable bowel syndrome (IBS). Several single-nucleotide polymorphisms (SNPs) have been associated with IBS. However, the impact of IBS genetics on the clinical course of IBD, especially pain levels of patients remains unclear., Methods: Data of 857 UC and 1206 CD patients from the Swiss IBD Cohort Study were analysed. We tested the association of the maximum of the abdominal pain item of disease activity indices in UC and CD over the study period with 16 IBS-associated SNPs, using multivariate ANOVA models., Results: In UC patients, the SNPs rs1042713 (located on the ADRB2 gene) and rs4663866 (close to the HES6 gene) were associated with higher abdominal pain levels (P = 0.044; P = 0.037, respectively). Abdominal pain was not associated with any markers of patient management in a model adjusted for confounders. In CD patients, higher levels of abdominal pain correlated with the number of physician contacts (P < 10
-15 ), examinations (P < 10-12 ), medical therapies (P = 0.023) and weeks of hospitalisation (P = 0.0013) in a multivariate model., Conclusions: We detected an association between maximal abdominal pain in UC patients and two IBS-associated SNPs. Abdominal pain levels had a pronounced impact on diagnostic and therapeutic procedures in CD but not in UC patients.- Published
- 2021
- Full Text
- View/download PDF
12. Fatigue in inflammatory bowel disease and its impact on daily activities.
- Author
-
Schreiner P, Rossel JB, Biedermann L, Valko PO, Baumann CR, Greuter T, Scharl M, Vavricka SR, Pittet V, Juillerat P, Rogler G, von Känel R, and Misselwitz B
- Subjects
- Anxiety, Cohort Studies, Fatigue epidemiology, Fatigue etiology, Female, Humans, Severity of Illness Index, Surveys and Questionnaires, Inflammatory Bowel Diseases complications, Inflammatory Bowel Diseases diagnosis, Inflammatory Bowel Diseases epidemiology, Quality of Life
- Abstract
Background: Fatigue is a common symptom of chronic inflammation, including inflammatory bowel disease (IBD), resulting in significant impairment in quality of life., Aims: To identify the prevalence of fatigue in a large IBD cohort compared to the general population, address risk factors, and evaluate its impact on daily life., Methods: We evaluated 1208 IBD patients from the Swiss Inflammatory Bowel Disease Cohort Study (SIBDCS) and 414 healthy controls. Significant fatigue was defined as a visual analogue scale (VAS-F, range 0-10) score ≥ 4. Secondary endpoints were severity of fatigue and its impact on daily activities with the Fatigue Severity Scale (FSS), with a score ≥ 4 indicative of fatigue. Demographic, IBD-related and psychiatric symptoms were assessed with a multivariate analysis of variance (MANOVA) model optimised for prediction of VAS-F (primary outcome) and FSS scores., Results: Overall, 672 IBD patients (55.6%) reported significant fatigue compared to 145 (35%) controls (OR 2.71; 95% CI 2.08-3.54; P < 0.001). In IBD, fatigue also significantly affected daily activities (FSS ≥ 4; 405 (33.5%) IBD patients vs 81 (19.6%) controls, P < 0.001). In the MANOVA model, fatigue levels were associated with female gender (coefficient 0.839; 0.556 - 1.123; P < 0.001), younger age at diagnosis (-0.031 per year; -0.042- -0.019; P < 0.001), shorter disease duration (-0.036 per year; -0.050- -0.022; P < 0.001), nocturnal diarrhoea (0.718; 0.295-1.141; P = 0.001), low educational level (P = 0.034) and symptoms of depression and anxiety., Conclusions: Fatigue is both more frequent and more severe in patients with IBD than in the general population., (© 2020 John Wiley & Sons Ltd.)
- Published
- 2021
- Full Text
- View/download PDF
13. Aortic Stiffening Is an Extraintestinal Manifestation of Inflammatory Bowel Disease: Review of the Literature and Expert Panel Statement.
- Author
-
Zanoli L, Mikhailidis DP, Bruno RM, Abreu MT, Danese S, Eliakim R, Gionchetti P, Katsanos KH, Kirchgesner J, Koutroubakis IE, Kucharzik T, Lakatos PL, Nguyen GC, Papa A, Vavricka SR, Wilkinson IB, and Boutouyrie P
- Subjects
- Animals, Anti-Inflammatory Agents therapeutic use, Cardiovascular Diseases immunology, Cardiovascular Diseases physiopathology, Cardiovascular Diseases prevention & control, Humans, Immunosuppressive Agents therapeutic use, Inflammatory Bowel Diseases drug therapy, Inflammatory Bowel Diseases immunology, Risk Factors, Treatment Outcome, Tumor Necrosis Factor Inhibitors therapeutic use, Cardiovascular Diseases etiology, Inflammatory Bowel Diseases complications, Vascular Stiffness drug effects
- Abstract
Current guidelines state that systemic inflammation, together with endothelial dysfunction, calcification, and hypercoagulability, predispose to premature atherosclerosis in patients with inflammatory bowel disease (IBD). We assessed whether IBD can affect aortic stiffness, a well-recognized vascular biomarker and an independent risk factor for cardiovascular (CV) disease (CVD) in several populations. Recent studies reported that aortic stiffness is increased in adults with IBD compared with matched controls. This association is dependent on inflammatory burden and disease duration, and is reduced by antitumor necrosis factor therapy. Considered together, current findings suggest that increased aortic stiffness is an extraintestinal manifestation of IBD. This is clinically relevant since measuring aortic stiffness in patients with IBD could improve risk assessment, especially in those without established CVD. Moreover, effective control of inflammation could lower CV risk in patients with IBD by reducing aortic stiffness. Further longitudinal studies are needed to better clarify (i) the relationship between disease duration and irreversible changes of the arterial wall, (ii) the clinical characteristics of patients with IBD that have an increased arterial stiffness at least in part reversible, and (iii) whether arterial stiffness is useful to evaluate the efficacy of immunosuppressive therapy.
- Published
- 2020
- Full Text
- View/download PDF
14. Interstitial and Granulomatous Lung Disease in Inflammatory Bowel Disease Patients.
- Author
-
Eliadou E, Moleiro J, Ribaldone DG, Astegiano M, Rothfuss K, Taxonera C, Ghalim F, Carbonnel F, Verstockt B, Festa S, Maia L, Berrozpe A, Zagorowicz E, Savarino E, Ellul P, Vavricka SR, Calvo M, Koutroubakis I, Hoentjen F, Salazar LF, Callela F, Cañete Pizarro F, Soufleris K, Sonnenberg E, Cavicchi M, Wypych J, Hommel C, Ghiani A, and Fiorino G
- Subjects
- Comorbidity, Female, Global Health statistics & numerical data, Glucocorticoids administration & dosage, Hospitalization statistics & numerical data, Humans, Lung Transplantation methods, Lung Transplantation statistics & numerical data, Male, Middle Aged, Outcome and Process Assessment, Health Care, Symptom Assessment statistics & numerical data, Anti-Inflammatory Agents adverse effects, Anti-Inflammatory Agents classification, Drug-Related Side Effects and Adverse Reactions diagnosis, Drug-Related Side Effects and Adverse Reactions epidemiology, Drug-Related Side Effects and Adverse Reactions therapy, Inflammatory Bowel Diseases diagnosis, Inflammatory Bowel Diseases epidemiology, Inflammatory Bowel Diseases therapy, Lung Diseases, Interstitial chemically induced, Lung Diseases, Interstitial diagnosis, Lung Diseases, Interstitial epidemiology, Lung Diseases, Interstitial therapy
- Abstract
Background: Interstitial lung [ILD] disease and granulomatous lung disease [GLD] are rare respiratory disorders that have been associated with inflammatory bowel disease [IBD]. Clinical presentation is polymorphic and aetiology is unclear., Methods: This was an ECCO-CONFER project. Cases of concomitant ILD or GLD and IBD, or drug-induced ILD/GLD, were collected. The criteria for diagnosing ILD and GLD were based on definitions from the American Thoracic Society and the European Respiratory Society and on the discretion of reporting clinician., Results: We identified 31 patients with ILD. The majority had ulcerative colitis [UC] [n = 22]. Drug-related ILD was found in 64% of these patients, 25 patients [80.6%] required hospitalisation, and one required non-invasive ventilation. The causative drug was stopped in all drug-related ILD, and 87% of patients received systemic steroids. At follow-up, 16% of patients had no respiratory symptoms, 16% had partial improvement, 55% had ongoing symptoms, and there were no data in 13%. One patient was referred for lung transplantation, and one death from lung fibrosis was reported. We also identified 22 GLD patients: most had Crohn's disease [CD] [n = 17]. Drug-related GLD was found in 36% of patients and 10 patients [45.4%] required hospitalisation. The causative drug was stopped in all drug-related GLD, and 81% of patients received systemic steroids. Remission of both conditions was achieved in almost all patients., Conclusions: ILD and GLD, although rare, can cause significant morbidity. In our series, over half of cases were drug-related and therefore focused pharmacovigilance is needed to identify and manage these cases., (© Crown copyright 2019.)
- Published
- 2020
- Full Text
- View/download PDF
15. Systematic analysis of therapeutic patterns and healthcare use during 12 months before inflammatory bowel disease-related hospitalization in Switzerland.
- Author
-
Schoepfer A, Vavricka SR, Brüngger B, Blozik E, and Bähler C
- Subjects
- Health Care Costs, Hospitalization, Humans, Switzerland, Colitis, Ulcerative diagnosis, Colitis, Ulcerative drug therapy, Inflammatory Bowel Diseases
- Abstract
Background and Aims: Given the lack of data, we aimed to systematically analyze therapeutic patterns and health resource utilization in the year before inflammatory bowel disease (IBD)-related hospitalization., Methods: Based on claims data of the Helsana health insurance group, therapy patterns and health resource utilization were assessed, and costs reimbursed by mandatory basic health insurance were calculated during a one-year period before an index hospitalization between 1 January 2013 to 31 December 2015., Results: We analyzed 344 IBD patients (140 ulcerative colitis [40.7%], 204 Crohn's disease [59.3%]). Drug regimens applied in the year before index hospitalization were as follows: no IBD drugs (43.6% ulcerative colitis, 43.1% Crohn's disease); 5-ASA (45.7% ulcerative colitis, 19.1% Crohn's disease); local steroids (17.9% ulcerative colitis, 17.6% Crohn's disease); systemic steroids (38.6% ulcerative colitis, 29.4% Crohn's disease); immunomodulators (10.7% ulcerative colitis, 18.1% Crohn's disease); biologics (10% ulcerative colitis, 24% Crohn's disease); and calcineurin inhibitors (2.1% ulcerative colitis, 1.5% Crohn's disease). Forty-five percent of ulcerative colitis patients and 31.4% of Crohn's disease patients had no diagnostic procedures [computed tomography (CT), MRI, radiograph, sonography, colonoscopy, and calprotectin] in the year before hospitalization. Total annual health care costs before index hospitalization was EUR 4060 (interquartile range (IQR) 2360-7390) for ulcerative colitis and EUR 4900 (IQR 1520-14 880) for Crohn's disease patients, respectively., Conclusions: Over 40% of ulcerative colitis and Crohn's disease patients did not receive any treatment in the year before index hospitalization. Efforts should be launched to timely diagnose and adequately treat IBD outpatients.
- Published
- 2020
- Full Text
- View/download PDF
16. Special Issue of Digestion: Inflammatory Bowel Disease.
- Author
-
Rogler G, König A, and Vavricka SR
- Subjects
- Digestion, Humans, Colitis, Inflammatory Bowel Diseases diagnosis, Inflammatory Bowel Diseases therapy
- Published
- 2020
- Full Text
- View/download PDF
17. Nutrition in Inflammatory Bowel Disease.
- Author
-
Schreiner P, Martinho-Grueber M, Studerus D, Vavricka SR, Tilg H, and Biedermann L
- Subjects
- Diet, Humans, Colitis, Ulcerative epidemiology, Crohn Disease epidemiology, Inflammatory Bowel Diseases epidemiology, Inflammatory Bowel Diseases etiology
- Abstract
Background: Westernization, above all associated changes in diet, has been postulated to be one of the most important factors contributing to the increasing incidence in inflammatory bowel disease (IBD), consisting mainly of Crohn's disease and ulcerative colitis., Summary: Diet represents a crucially important and intuitively relevant topic for IBD patients. Although a substantial number of patients are prone to follow dietary advice from a variety of sources, including the lay press, there is intriguingly little scientific evidence for such an incitement. This may result in physicians being insufficiently informed about various aspects of nutrition, precluding adequate guidance of their patients with IBD. Importantly, IBD patients are at risk to develop deficiencies in iron, vitamin B12, folic acid, and several micronutrients, which may even be more pronounced in patients with active disease and those following a restrictive diet. This review aims to summarize the latest data from clinical and epidemiological studies investigating diet and its effect on the course of the disease and to outline the most important nutrient deficiencies in IBD patients. Key Messages: A western diet with an imbalance between omega-6 (n-6)/omega-3 (n-3) polyunsaturated fatty acids (PUFAs), in favor of n-6 PUFAs, may increase the risk of IBD, whereas a diet high in fruits and vegetables may decrease the risk of IBD. Many approaches to influence the course of IBD with dietary intervention exist. However, to induce or maintain remission in IBD with a change of diet is still in its infancy, and more dietary research is needed before we can apply it in daily practice. Patients with IBD, even in remission, have to be screened regularly for malnutrition., (© 2020 S. Karger AG, Basel.)
- Published
- 2020
- Full Text
- View/download PDF
18. Therapies in Inflammatory Bowel Disease Patients with Extraintestinal Manifestations.
- Author
-
Juillerat P, Manz M, Sauter B, Zeitz J, and Vavricka SR
- Subjects
- Antibodies, Monoclonal, Humans, Tumor Necrosis Factor-alpha, Colitis, Inflammatory Bowel Diseases complications, Inflammatory Bowel Diseases drug therapy
- Abstract
Extraintestinal manifestations (EIM) have become an important source of morbidity and disability as well as an identified risk factor for an unfavorably course of disease in inflammatory bowel diseases (IBD). Therefore, efforts have been put into a more global and interdisciplinary management of IBD patients in collaboration with rheumatologists, dermatologists, and ophthalmologists. A real therapeutic success has also been obtained with a more "systemic" IBD treatment associated with the development of monoclonal antibodies against TNF alpha and biological agents derived from the treatment of rheumatological disease (also called biological Disease-Modifying Antirheumatic Drugs). The prevalence of these EIM remains too low to undergo randomized controlled trials with this specific focus and therefore the evidence relies on case series and experts' opinions, which lowers the level of evidence. After a careful review of the most recent literature, this paper aims to update the reader on the latest therapeutic management of IBD patients with EIM., (© 2020 S. Karger AG, Basel.)
- Published
- 2020
- Full Text
- View/download PDF
19. Gender Differences in Inflammatory Bowel Disease.
- Author
-
Greuter T, Manser C, Pittet V, Vavricka SR, and Biedermann L
- Subjects
- Disease Progression, Female, Humans, Severity of Illness Index, Sex Factors, Colitis, Inflammatory Bowel Diseases diagnosis, Inflammatory Bowel Diseases epidemiology, Inflammatory Bowel Diseases therapy
- Abstract
Immune-mediated diseases typically show a female preponderance. Looking at all autoimmune diseases combined, 8 of 10 patients are females. Although not as prominent, gender differences in inflammatory bowel disease (IBD) have been reported for epidemiology, disease presentation, disease course and complications, medical and surgical therapies, adherence, psychosocial functioning, and psychiatric co-disorders. While for some factors evidence is rather good, for others data are conflicting. Gastroenterologists dealing with IBD patients in daily clinical practice should be aware of gender-specific issues for the following reasons: (1) misperception of disease presentation potentially delays IBD diagnosis, which has been shown to have deleterious effects, and (2) awareness of gender-specific symptoms and disease severity allows initiation of early and adequately tailored treatment. This might prevent development of complications. And (3) insights into gender-specific differences in terms of treatment and adherence to treatment can improve disease management and foster a more individualized treatment approach. In this review, we summarize current knowledge about gender-specific differences in IBD and highlight the most clinically relevant aspects., (© 2020 S. Karger AG, Basel.)
- Published
- 2020
- Full Text
- View/download PDF
20. Therapeutic Drug Monitoring to Guide Clinical Decision Making in Inflammatory Bowel Disease Patients with Loss of Response to Anti-TNF: A Delphi Technique-Based Consensus.
- Author
-
Greuter T, Maillard MH, Juillerat P, Michetti P, Seibold F, Mottet C, Zahnd N, Sauter B, Schoepfer AM, Rogler G, and Vavricka SR
- Subjects
- Adalimumab, Clinical Decision-Making, Consensus, Europe, Humans, Infliximab, Switzerland, Tumor Necrosis Factor-alpha, Delphi Technique, Drug Monitoring, Inflammatory Bowel Diseases drug therapy, Tumor Necrosis Factor Inhibitors
- Abstract
Background: Loss of response is frequently encountered in patients with inflammatory bowel disease (IBD) treated with antitumor necrosis factor (TNF) agents. Therapeutic drug monitoring (TDM) and antidrug antibody measurement are increasingly used in this setting., Methods: To establish a consensus on the use of TDM in the context of loss of response to anti-TNFs, we performed a vote using a Delphi-style process followed by an expert panel discussion among 8 IBD specialists practicing in Switzerland, Europe. Statements were rated on an even Likert-scale ranging from 1 (strong disagreement) to 4 (strong agreement), based on expert opinion and the available literature., Results: The experts agreed on the following statements: (i) loss of response is associated with inadequate drug levels in both Crohn's disease and ulcerative colitis; (ii) best timepoint for measuring drug levels is prior to the next application (= trough levels) with different thresholds for anti-TNF agents (infliximab 5 μg/mL, adalimumab 8 μg/mL, certolizumab pegol 10 μg/mL); (iii) antidrug antibodies are predictive for loss of response; and (iv) antidrug-antibody titers and drug trough levels are key determinants in the treatment algorithm. Data about non-anti-TNF biologics were considered too limited to propose recommendations., Conclusion: A Delphi-style consensus among 8 IBD experts shows that TDM and measurement of antidrug-antibody titers are useful in the context of loss of response to anti-TNF. Optimal cutoff levels depend on the type of anti-TNF. These values are critical in the decision making process. More studies are needed to address the value of such measurements for non-anti-TNF biologics., (© 2019 S. Karger AG, Basel.)
- Published
- 2020
- Full Text
- View/download PDF
21. Response to Al Sulais et al.
- Author
-
Greuter T, Vavricka SR, and Scharl M
- Subjects
- Cohort Studies, Humans, Incidence, Risk Factors, Inflammatory Bowel Diseases, Neoplasms
- Published
- 2019
- Full Text
- View/download PDF
22. Vegetarian or gluten-free diets in patients with inflammatory bowel disease are associated with lower psychological well-being and a different gut microbiota, but no beneficial effects on the course of the disease.
- Author
-
Schreiner P, Yilmaz B, Rossel JB, Franc Y, Misselwitz B, Scharl M, Zeitz J, Frei P, Greuter T, Vavricka SR, Pittet V, Siebenhüner A, Juillerat P, von Känel R, Macpherson AJ, Rogler G, and Biedermann L
- Subjects
- Adult, Aged, Female, Humans, Inflammatory Bowel Diseases diagnosis, Inflammatory Bowel Diseases epidemiology, Interview, Psychological, Male, Middle Aged, Public Health Surveillance, Surveys and Questionnaires, Treatment Outcome, Diet, Gluten-Free, Diet, Vegetarian, Gastrointestinal Microbiome, Inflammatory Bowel Diseases diet therapy, Inflammatory Bowel Diseases psychology
- Abstract
Background: Many inflammatory bowel disease (IBD) patients follow a restrictive diet due to perceived positive effects on their symptoms. We assessed the prevalence of vegetarian (VD) and gluten-free diets (GFDs) in IBD patients, the reasons for following such a diet, and whether nutrition has an impact on disease activity and microbiota composition., Methods: We included 1254 patients from the Swiss Inflammatory Bowel Disease Cohort Study with prospective acquisition of clinical data and psychosocial, disease-related and lifestyle factors between 2006 and 2015. Dietary habits were assessed through a self-report questionnaire. In 92 patients, we analysed intestinal mucosa-associated microbial composition using high-throughput sequencing., Results: Overall, 4.1% ( n = 52) of the patients reported following a VD and 4.7% ( n = 54) a GFD. No differences regarding disease activity, fistula, hospitalization or surgery rates were observed. Patients on a VD or GFD had significantly higher levels of post-traumatic stress symptoms. Furthermore, GFD patients had significantly higher anxiety and depression symptom levels. The gut microbiota composition in IBD patients following a VD or GFD was significantly different compared to that of omnivores., Conclusions: Although we did not identify a relevant impact of a specific diet on the course of the disease, there was a significant association with lower psychological well-being in VD and GFD patients.
- Published
- 2019
- Full Text
- View/download PDF
23. European Crohn's and Colitis Organisation Topical Review on Complementary Medicine and Psychotherapy in Inflammatory Bowel Disease.
- Author
-
Torres J, Ellul P, Langhorst J, Mikocka-Walus A, Barreiro-de Acosta M, Basnayake C, Ding NJS, Gilardi D, Katsanos K, Moser G, Opheim R, Palmela C, Pellino G, Van der Marel S, and Vavricka SR
- Subjects
- Cognitive Behavioral Therapy methods, Consensus, Dietary Supplements, Europe, Herbal Medicine methods, Humans, Mind-Body Therapies methods, Societies, Medical, Complementary Therapies methods, Inflammatory Bowel Diseases therapy, Psychotherapy methods
- Abstract
Patients with inflammatory bowel disease [IBD] increasingly use alternative and complementary therapies, for which appropriate evidence is often lacking. It is estimated that up to half of all patients with IBD use various forms of complementary and alternative medicine during some point in their disease course. Considering the frequent use of such therapies, it is crucial that physicians and patients are informed about their efficacy and safety in order to provide guidance and evidence-based advice. Additionally, increasing evidence suggests that some psychotherapies and mind-body interventions may be beneficial in the management of IBD, but their best use remains a matter of research. Herein, we provide a comprehensive review of some of the most commonly used complementary, alternative and psychotherapy interventions in IBD., (Copyright © 2019 European Crohn’s and Colitis Organisation (ECCO). Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oup.com.)
- Published
- 2019
- Full Text
- View/download PDF
24. Extraintestinal manifestations in inflammatory bowel disease - epidemiology, genetics, and pathogenesis.
- Author
-
Greuter T and Vavricka SR
- Subjects
- Genetic Predisposition to Disease, Humans, Immunosuppressive Agents adverse effects, Phenotype, Prognosis, Risk Assessment, Risk Factors, Digestive System Diseases epidemiology, Digestive System Diseases genetics, Digestive System Diseases immunology, Digestive System Diseases therapy, Eye Diseases epidemiology, Eye Diseases genetics, Eye Diseases immunology, Eye Diseases therapy, Inflammatory Bowel Diseases drug therapy, Inflammatory Bowel Diseases epidemiology, Inflammatory Bowel Diseases genetics, Inflammatory Bowel Diseases immunology, Joint Diseases epidemiology, Joint Diseases genetics, Joint Diseases immunology, Joint Diseases therapy, Skin Diseases epidemiology, Skin Diseases genetics, Skin Diseases immunology, Skin Diseases therapy
- Abstract
Introduction: Inflammatory bowel disease (IBD) is a chronic inflammatory disorder, primarily of, but not restricted to the gut. Extraintestinal manifestations (EIMs) are frequently observed and involve the joints, eyes, hepatobiliary tract, and skin. Areas covered: In this review, we discuss classical EIM focusing on epidemiology, genetics, and pathogenesis, highlighting recent advances in the understanding of EIM. We further discuss treatment-induced immunological phenomena, which are increasingly recognized and might challenge IBD-treating physicians in the era of biological treatment. Expert opinion: EIM considerably contributes to morbidity and mortality. Genetic studies have revealed a common genetic background between EIM and IBD and among specific EIM. Identified protein interactions have been shown to cluster in shared biological pathways. However - despite these recent advances - pathogenesis of EIM is at best partially understood. Several pathogenic mechanisms have been proposed such as upregulation of tumor necrosis factor, aberrant lymphocyte homing, and cross-reactive antigen presentation. It still remains unclear whether EIM is a direct result of the inflammatory process in the gut or rather a consequence of a shared genetic background leading to dysfunctional immune responses to environmental stimuli. Exploration and understanding of EIM genetics and pathophysiology will pave the road for better and more efficacious treatment options in the future.
- Published
- 2019
- Full Text
- View/download PDF
25. ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 2: IBD scores and general principles and technical aspects.
- Author
-
Sturm A, Maaser C, Calabrese E, Annese V, Fiorino G, Kucharzik T, Vavricka SR, Verstockt B, van Rheenen P, Tolan D, Taylor SA, Rimola J, Rieder F, Limdi JK, Laghi A, Krustiņš E, Kotze PG, Kopylov U, Katsanos K, Halligan S, Gordon H, González Lama Y, Ellul P, Eliakim R, Castiglione F, Burisch J, Borralho Nunes P, Bettenworth D, Baumgart DC, and Stoker J
- Subjects
- Diagnostic Imaging methods, Humans, International Cooperation, Severity of Illness Index, Symptom Assessment methods, Symptom Assessment standards, Endoscopy, Gastrointestinal methods, Endoscopy, Gastrointestinal standards, Inflammatory Bowel Diseases diagnosis, Intestines diagnostic imaging, Research Design standards
- Published
- 2019
- Full Text
- View/download PDF
26. Feasibility of an 8-item questionnaire for early diagnosis of inflammatory bowel disease in primary care.
- Author
-
Chmiel C, Vavricka SR, Hasler S, Rogler G, Zahnd N, Schiesser S, Tandjung R, Scherz N, Rosemann T, and Senn O
- Subjects
- Biomarkers analysis, Diagnostic Techniques, Digestive System psychology, Diagnostic Techniques, Digestive System statistics & numerical data, Feasibility Studies, Feces, Female, Humans, Male, Middle Aged, Quality Improvement, Switzerland, Early Diagnosis, Inflammatory Bowel Diseases diagnosis, Leukocyte L1 Antigen Complex analysis, Patient Preference, Primary Health Care methods, Primary Health Care standards, Surveys and Questionnaires
- Abstract
Aims: Diagnosis of inflammatory bowel disease (IBD) is often associated with a diagnostic delay. Although faecal calprotectin is a helpful screening tool, the widespread use in primary care (PC) may not be appropriate due to the low prevalence of IBD in this setting. To increase pretest probability for a positive calprotectin test, an 8-item questionnaire (CalproQuest) was tested for its feasibility and acceptability in PC., Methods: Population: PC patients with unspecific gastrointestinal complaints for at least 2 weeks. The CalproQuest consists of four major and four minor questions specific for IBD. It is considered positive if greater than or equal to two major or one major and two minor criteria are positive., Primary Outcome: feasibility of CalproQuest, secondary outcome: patient's acceptance of stool sampling., Results: Of 95 patients with a complete CalproQuest 52 (54.7%) were positive, 39 (41.1%) fulfilled two major and 13 (13.7%) one major and greater than or equal to two minor criteria. Twenty-seven general practitioners completed 83 (87.4%) questionnaires on feasibility which was assessed positive. Eighty-two patients (86.3%) completed questionnaires on acceptance which was high., Conclusion: The CalproQuest is a feasible instrument for assessing IBD in PC. Further prospective studies concerning validity and cost effectiveness of a combined use with the calprotectin test in this setting are necessary., (© 2018 John Wiley & Sons, Ltd.)
- Published
- 2019
- Full Text
- View/download PDF
27. ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, detection of complications.
- Author
-
Maaser C, Sturm A, Vavricka SR, Kucharzik T, Fiorino G, Annese V, Calabrese E, Baumgart DC, Bettenworth D, Borralho Nunes P, Burisch J, Castiglione F, Eliakim R, Ellul P, González-Lama Y, Gordon H, Halligan S, Katsanos K, Kopylov U, Kotze PG, Krustinš E, Laghi A, Limdi JK, Rieder F, Rimola J, Taylor SA, Tolan D, van Rheenen P, Verstockt B, and Stoker J
- Subjects
- Diagnosis, Differential, Humans, International Cooperation, Monitoring, Physiologic methods, Diagnostic Techniques, Digestive System standards, Endoscopy, Gastrointestinal methods, Inflammatory Bowel Diseases complications, Inflammatory Bowel Diseases diagnosis
- Published
- 2019
- Full Text
- View/download PDF
28. Malignancies in Inflammatory Bowel Disease: Frequency, Incidence and Risk Factors-Results from the Swiss IBD Cohort Study.
- Author
-
Scharl S, Barthel C, Rossel JB, Biedermann L, Misselwitz B, Schoepfer AM, Straumann A, Vavricka SR, Rogler G, Scharl M, and Greuter T
- Subjects
- Adult, Cohort Studies, Colorectal Neoplasms complications, Cross-Sectional Studies, Female, Humans, Incidence, Inflammatory Bowel Diseases complications, Longitudinal Studies, Male, Regression Analysis, Risk Factors, Switzerland epidemiology, Young Adult, Colorectal Neoplasms epidemiology, Inflammatory Bowel Diseases epidemiology
- Abstract
Background: Malignancy may occur as long-term complication of inflammatory bowel disease (IBD) due to different risk factors. We assessed prevalence and incidence of malignancy, and predictive factors in the Swiss IBD Cohort Study (SIBDCS)., Methods: All IBD patients in the SIBDCS were analyzed from a cross-sectional and longitudinal perspective. Patients with malignancies were compared to controls. Standardized incidence ratios (SIR) were calculated based on age-specific and sex-specific background rates., Results: Malignancies were identified in 122 of 3119 patients (3.9%). In a logistic regression model, age (OR 1.04 per year), intestinal surgery (OR 3.34), and treatment with steroids (OR 2.10) were the main predictors for the presence of malignancy, while treatment with 5-ASA (OR 0.57) and biologics (OR 0.38) were protective. From a longitudinal perspective, 67 out of 2580 patients (2.6%) were newly diagnosed with malignancy during a follow-up of 12,420.8 years (median 4.9 years). While there was no increased risk for malignancy overall (SIR 0.93, 95% CI 0.72-1.18) and colorectal cancer (SIR 1.55, 95% CI 0.71-2.95), IBD patients had an increased risk for lymphoma (SIR 2.98, 95% CI 1.36-5.66) and biliary cancer (SIR 6.3, 95% CI 1.27-18.41). In a Cox regression model, age and recent use of immunomodulators were the main predictors for development of malignancies, while 5-ASA, biologics were protective., Conclusions: IBD patients showed increased risk for lymphoma and biliary cancer, but not colorectal cancer and cancer overall. Age and recent use of immunomodulators were the main risk factors for malignancy, while aminosalicylates and biologics appear to be protective.
- Published
- 2019
- Full Text
- View/download PDF
29. [Extraintestinal manifestations in chronic inflammatory bowel diseases].
- Author
-
Vavricka SR, Greuter T, and Zeitz J
- Subjects
- Biliary Tract Diseases etiology, Eye Diseases etiology, Humans, Musculoskeletal Diseases etiology, Quality of Life, Skin Diseases etiology, Colitis, Ulcerative complications, Crohn Disease complications, Inflammatory Bowel Diseases complications
- Abstract
Extraintestinal manifestations in chronic inflammatory bowel diseases Abstract. Chronic inflammatory bowel diseases (IBD) are inflammatory gastrointestinal disorders that are not limited to the gastrointestinal tract. Various organ systems may be involved, making IBD a systemic disease. The most common extraintestinal manifestations (EIMs) include musculoskeletal, ophthalmic, dermatological and hepato-biliary disorders. EIMs considerably contribute to the morbidity of patients with IBD and also limit their quality of life. Due to the diversity of the organ systems involved, care should be provided on an interdisciplinary basis by a medical staff trained in the treatment of IBD. Early detection of EIM allows targeted therapy and reduces the overall morbidity of the affected patients. Of importance is the fact that EIM can occur in up to 25 % of all IBD patients before the onset of the first Crohn's episode or ulcerative colitis. Therefore, dermatologists, ophthalmologists and rheumatologists should beware of this possible association in EIM and the simultaneous occurrence of intestinal symptoms.
- Published
- 2019
- Full Text
- View/download PDF
30. Environmental triggers in IBD: a review of progress and evidence.
- Author
-
Ananthakrishnan AN, Bernstein CN, Iliopoulos D, Macpherson A, Neurath MF, Ali RAR, Vavricka SR, and Fiocchi C
- Subjects
- Humans, Inflammatory Bowel Diseases diagnosis, Inflammatory Bowel Diseases therapy, Risk Factors, Socioeconomic Factors, Environment, Inflammatory Bowel Diseases etiology
- Abstract
A number of environmental factors have been associated with the development of IBD. Alteration of the gut microbiota, or dysbiosis, is closely linked to initiation or progression of IBD, but whether dysbiosis is a primary or secondary event is unclear. Nevertheless, early-life events such as birth, breastfeeding and exposure to antibiotics, as well as later childhood events, are considered potential risk factors for IBD. Air pollution, a consequence of the progressive contamination of the environment by countless compounds, is another factor associated with IBD, as particulate matter or other components can alter the host's mucosal defences and trigger immune responses. Hypoxia associated with high altitude is also a factor under investigation as a potential new trigger of IBD flares. A key issue is how to translate environmental factors into mechanisms of IBD, and systems biology is increasingly recognized as a strategic tool to unravel the molecular alterations leading to IBD. Environmental factors add a substantial level of complexity to the understanding of IBD pathogenesis but also promote the fundamental notion that complex diseases such as IBD require complex therapies that go well beyond the current single-agent treatment approach. This Review describes the current conceptualization, evidence, progress and direction surrounding the association of environmental factors with IBD.
- Published
- 2018
- Full Text
- View/download PDF
31. Trends in prevalence, mortality, health care utilization and health care costs of Swiss IBD patients: a claims data based study of the years 2010, 2012 and 2014.
- Author
-
Bähler C, Vavricka SR, Schoepfer AM, Brüngger B, and Reich O
- Subjects
- Adolescent, Adult, Aged, Child, Child, Preschool, Drug Costs, Female, Hospitalization economics, Humans, Infant, Inflammatory Bowel Diseases mortality, Inflammatory Bowel Diseases therapy, Male, Middle Aged, Prevalence, Retrospective Studies, Switzerland epidemiology, Young Adult, Health Care Costs, Inflammatory Bowel Diseases economics, Inflammatory Bowel Diseases epidemiology, Patient Acceptance of Health Care
- Abstract
Background: Real-life data on inflammatory bowel disease (IBD) prevalence and costs are scarce. The aims of this study were to provide an overview of the prevalence, mortality, health care utilization and costs of IBD patients in Switzerland in the years 2010, 2012, and 2014., Methods: Based on claims data of the Helsana-Group, prevalence of IBD was assessed for 2010, 2012 and 2014. Mortality rates, costs (inpatient, outpatient, medication costs) and utilization (visits, hospitalizations) were compared between patients with and without IBD, and between IBD patients treated with and without biologics. Results were extrapolated to the Swiss general population using national census data. Multivariate linear regression was used to identify socio-demographic and regional factors influencing total costs., Results: The overall extrapolated prevalence rates of IBD were 0.32% in 2010, 0.38% in 2012, and 0.41% in 2014. Mortality rate didn't differ between the IBD and non-IBD population. Costs increased annually by 6% in IBD versus 2.4% in non-IBD subjects, which was solely due to increased outpatient costs. Almost one-fourth of IBD patients were hospitalized at least once a year. Costs were higher in IBD patients treated with biologics (OR = 3.98, CI: 3.72-4.27, p < 0.001) when compared to IBD patients without biologic therapies. Over 70% of the total costs in IBD patients treated with biologics were due to drug costs, compared with 28% in patients without use of biologic therapies, whereas inpatient costs didn't differ., Conclusions: The prevalence of IBD seems to be increasing in Switzerland. Outpatient costs increased substantially, while no decrease in inpatient costs was found. Treatment of IBD is more and more based on biologic therapies.
- Published
- 2017
- Full Text
- View/download PDF
32. Skin Manifestations of Inflammatory Bowel Disease.
- Author
-
Greuter T, Navarini A, and Vavricka SR
- Subjects
- Erythema Nodosum, Humans, Inflammatory Bowel Diseases drug therapy, Infliximab therapeutic use, Pyoderma Gangrenosum, Skin immunology, Sweet Syndrome, Tumor Necrosis Factor-alpha metabolism, Inflammatory Bowel Diseases immunology, Skin pathology
- Abstract
Inflammatory bowel disease (IBD) with its two main subtypes Crohn's disease and ulcerative colitis is not restricted to the gastrointestinal tract. Indeed, so-called extraintestinal manifestations (EIMs) are frequent and considerably affect morbidity and mortality. The prevalence of EIMs ranges from 6 to 47%. In up to one quarter of the patients, EIMs can present even before an IBD diagnosis is established. The pathophysiology of EIMs remains elusive, although data from clinical trials demonstrating anti-tumor necrosis factor (TNF) efficacy suggest a common pathogenic link between intestinal and extraintestinal disease activity. However, not all EIMs parallel intestinal disease. Skin lesions are usually classified based on their pathophysiological association with the underlying intestinal disease into four categories: (1) specific, (2) reactive, (3) associated, and (4) treatment-induced manifestations. Cutaneous manifestations include erythema nodosum (EN), pyoderma gangrenosum (PG), Sweet's syndrome, and oral lesions, with EN being the most commonly reported and PG showing the most debilitating disease course. Anti-TNF-induced skin reactions are a new, but increasingly recognized phenomenon, which can be eventually misinterpreted as psoriatic lesions. Medical treatment modalities are limited with topical and systemic steroids being the most frequently employed agents. If EIMs parallel intestinal disease activity, the therapeutic cornerstone usually is the management of underlying intestinal disease activity rather than direct treatment of the EIMs. However, increasing evidence for anti-TNF agents' efficacy in EIM management has changed the approach to complicating and debilitating disease courses. In the case of anti-TNF-induced lesions, topical steroids are usually sufficient and discontinuation of anti-TNF is seldom warranted. In this review, we summarize current knowledge on cutaneous EIMs, their diagnostic criteria and clinical presentation, natural history, pathogenesis, and treatment options.
- Published
- 2017
- Full Text
- View/download PDF
33. Risk factors for gallstones and kidney stones in a cohort of patients with inflammatory bowel diseases.
- Author
-
Fagagnini S, Heinrich H, Rossel JB, Biedermann L, Frei P, Zeitz J, Spalinger M, Battegay E, Zimmerli L, Vavricka SR, Rogler G, Scharl M, and Misselwitz B
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Child, Child, Preschool, Female, Gallstones etiology, Hospitalization, Humans, Incidence, Kidney Calculi etiology, Male, Middle Aged, Prospective Studies, Risk Factors, Switzerland epidemiology, Time Factors, Young Adult, Gallstones epidemiology, Inflammatory Bowel Diseases complications, Kidney Calculi epidemiology
- Abstract
Background: Gallstones and kidney stones are known complications of inflammatory bowel diseases (IBD). Risk factors have been insufficiently studied and explanatory studies date back up to 30 years. It remains unclear, whether improved treatment options also influenced risk factors for these complications., Objectives: Identifying risk factors for gallstones and kidney stones in IBD patients., Methods: Using data from the Swiss Inflammatory Bowel Disease Cohort Study we assessed associations of diseases characteristics with gallstones and kidney stones in univariate and multivariate logistic regression analyses., Results: Out of 2323 IBD patients, 104 (7.8%) Crohn's disease (CD) and 38 (3.8%) ulcerative colitis (UC) patients were diagnosed with gallstones. Significant risk factors for gallstones were diagnosis of CD, age at diagnosis, disease activity and duration, NSAID intake, extra-intestinal manifestations and intestinal surgery. Kidney stones were described in 61 (4.6%) CD and 30 (3.0%) UC patients. Male gender, disease activity, intestinal surgery, NSAID usage and reduced physical activity were significant risk factors. Hospitalization was associated with gallstones and kidney stones. The presence of gallstones increased the risk for kidney stones (OR 4.87, p<0.001)., Conclusion: The diagnosis of CD, intestinal surgery, prolonged NSAID use, disease activity and duration and bowel stenosis were significantly associated with cholecystonephrolithiasis in IBD.
- Published
- 2017
- Full Text
- View/download PDF
34. Chronic comorbidities associated with inflammatory bowel disease: prevalence and impact on healthcare costs in Switzerland.
- Author
-
Bähler C, Schoepfer AM, Vavricka SR, Brüngger B, and Reich O
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Ambulatory Care economics, Case-Control Studies, Child, Child, Preschool, Comorbidity, Cross-Sectional Studies, Female, Humans, Infant, Inflammatory Bowel Diseases diagnosis, Inflammatory Bowel Diseases therapy, Linear Models, Male, Middle Aged, Models, Economic, Multiple Chronic Conditions therapy, Multivariate Analysis, Odds Ratio, Prevalence, Risk Factors, Switzerland epidemiology, Time Factors, Young Adult, Health Care Costs, Inflammatory Bowel Diseases economics, Inflammatory Bowel Diseases epidemiology, Multiple Chronic Conditions economics, Multiple Chronic Conditions epidemiology
- Abstract
Objective: Inflammatory bowel disease (IBD) was shown to be associated with a variety of chronic comorbidities. We aimed to evaluate the frequency of 21 chronic conditions and compared frequencies in IBD and non-IBD populations. Further, healthcare costs of those (additional) chronic conditions were calculated., Patients and Methods: A total of 4791 IBD patients, who were insured at Helsana Insurance Group in 2014, were compared with 1 114 638 individuals without IBD. Entropy balancing was performed to create balanced samples. Chronic conditions were identified by means of the updated Pharmacy-based Cost Group model. Multivariate log-transformed linear regression modeling was performed to estimate the effect of the morbidity status (non-IBD +none, +1, +2, and +3 or more chronic conditions) on the healthcare costs., Results: Overall, 78% of IBD patients had at least one comorbidity, with a median of three comorbidities. Largest differences between individuals with and without IBD were found for rheumatologic conditions, acid-related disorders, pain, bone diseases, migraines, cancer, and iron-deficiency anemia, whereas no significant differences between the two groups were found for diabetes, dementia, hyperlipidemia, glaucoma, gout, HIV, psychoses, and Parkinson's disease after adjustments for a variety of covariates. Each increase in the morbidity status led to increased healthcare costs; rheumatologic conditions, acid-related disorders, and pain as the most frequent comorbidities more than doubled total costs in IBD patients., Conclusion: We found a considerably high prevalence of concomitant chronic diseases in IBD patients. This was associated with considerably higher healthcare costs, especially in the outpatient setting.
- Published
- 2017
- Full Text
- View/download PDF
35. Anti-TNF Treatment for Extraintestinal Manifestations of Inflammatory Bowel Disease in the Swiss IBD Cohort Study.
- Author
-
Vavricka SR, Gubler M, Gantenbein C, Spoerri M, Froehlich F, Seibold F, Protic M, Michetti P, Straumann A, Fournier N, Juillerat P, Biedermann L, Zeitz J, Misselwitz B, Scharl M, Heinrich H, Manser CN, Safroneeva E, Raja Ali RA, Rogler G, Schoepfer AM, and Greuter T
- Subjects
- Adalimumab therapeutic use, Adolescent, Adult, Aged, Arthritis immunology, Arthritis pathology, Certolizumab Pegol therapeutic use, Child, Child, Preschool, Female, Follow-Up Studies, Humans, Inflammatory Bowel Diseases immunology, Inflammatory Bowel Diseases pathology, Infliximab therapeutic use, Male, Middle Aged, Prognosis, Stomatitis, Aphthous immunology, Stomatitis, Aphthous pathology, Young Adult, Arthritis drug therapy, Immunosuppressive Agents therapeutic use, Inflammatory Bowel Diseases drug therapy, Stomatitis, Aphthous drug therapy, Tumor Necrosis Factor-alpha immunology
- Abstract
Background: Extraintestinal manifestations (EIMs) in patients with inflammatory bowel disease (IBD) are frequently observed. Little is known about the efficacy of anti-tumor necrosis factor (TNF) in EIM management. We assessed the effect of 3 anti-TNF agents (infliximab, adalimumab, and certolizumab pegol) on EIM evolution., Methods: Data on 1249 patients from the Swiss IBD Cohort Study (SIBDCS) were analyzed. All EIMs were diagnosed by relevant specialists. Response was classified into improvement, stable disease, and clinical worsening based on the physician's interpretation., Results: Of the 366 patients with at least 1 EIM, 213 (58.2%) were ever treated with an anti-TNF. A total of 299 treatments were started for 355 EIMs. Patients with EIM were significantly more often treated with anti-TNF compared with those without EIM (58.2% versus 21.0%, P < 0.001). Infliximab was the most frequently used drug (63.2%). In more than 71.8%, a clinical response of the underlying EIM to anti-TNF therapy was observed. In 92 patients (43.2%), anti-TNF treatments were started for the purpose of treating EIM rather than IBD. Response rates to anti-TNF were generally good and best for psoriasis, aphthous stomatitis, uveitis, and peripheral arthritis. In 11 patients, 14 EIM occurred under anti-TNF treatment., Conclusions: Anti-TNF was frequently used among patients with EIM. In more than 40%, anti-TNF treatments are started to treat EIM rather than IBD. Given the good response rates, anti-TNF seems to be a valuable option in the treatment of EIM, whereas appearance of EIM under anti-TNF does not seem to be a source of considerable concern.
- Published
- 2017
- Full Text
- View/download PDF
36. Widely differing screening and treatment practice for osteoporosis in patients with inflammatory bowel diseases in the Swiss IBD cohort study.
- Author
-
Schüle S, Rossel JB, Frey D, Biedermann L, Scharl M, Zeitz J, Freitas-Queiroz N, Kuntzen T, Greuter T, Vavricka SR, Rogler G, and Misselwitz B
- Subjects
- Absorptiometry, Photon, Adolescent, Adult, Aged, Aged, 80 and over, Female, Humans, Inflammatory Bowel Diseases diagnosis, Inflammatory Bowel Diseases epidemiology, Inflammatory Bowel Diseases therapy, Logistic Models, Male, Middle Aged, Multivariate Analysis, Osteoporosis complications, Osteoporosis epidemiology, Prevalence, Prognosis, Prospective Studies, Risk Factors, Switzerland, Young Adult, Inflammatory Bowel Diseases complications, Osteoporosis diagnosis, Osteoporosis therapy
- Abstract
Low bone mineral density (BMD) and osteoporosis remain frequent problems in patients with inflammatory bowel diseases (IBDs). Several guidelines with nonidentical recommendations exist and there is no general agreement regarding the optimal approach for osteoporosis screening in IBD patients. Clinical practice of osteoporosis screening and treatment remains insufficiently investigated.In the year 2014, a chart review of 877 patients included in the Swiss IBD Cohort study was performed to assess details of osteoporosis diagnostics and treatment. BMD measurements, osteoporosis treatment, and IBD medication were recorded.Our chart review revealed 253 dual-energy x-ray absorptiometry (DXA) scans in 877 IBD patients; osteoporosis was prevalent in 20% of tested patients. We identified widely differing osteoporosis screening rates among centers (11%-62%). A multivariate logistic regression analysis identified predictive factors for screening including steroid usage, long disease duration, and perianal disease; even after correction for all risk factors, the study center remained a strong independent predictor (odds ratio 2.3-21 compared to the center with the lowest screening rate). Treatment rates for patients with osteoporosis were suboptimal (55% for calcium, 65% for vitamin D) at the time of chart review. Similarly, a significant fraction of patients with current steroid medication were not treated with vitamin D or calcium (treatment rates 53% for calcium, 58% for vitamin D). For only 29% of patients with osteoporosis bisphosphonate treatment was started. Treatment rates also differed among centers, generally following screening rates. In patients with longitudinal DXA scans, calcium and vitamin D usage was significantly associated with improvement of BMD over time.Our analysis identified inconsistent usage of osteoporosis screening and underuse of osteoporosis treatment in IBD patients. Increasing awareness of osteoporosis as a significant clinical problem in IBD patients might improve patient care.
- Published
- 2017
- Full Text
- View/download PDF
37. Cytomegalovirus disease in inflammatory bowel disease: epidemiology and disease characteristics in a large single-centre experience.
- Author
-
Bontà J, Zeitz J, Frei P, Biedermann L, Sulz MC, Vavricka SR, Scharl S, Fried M, Rogler G, and Scharl M
- Subjects
- Adult, Antiviral Agents therapeutic use, Cytomegalovirus Infections diagnosis, Cytomegalovirus Infections drug therapy, Cytomegalovirus Infections epidemiology, Cytomegalovirus Infections immunology, Female, Gastrointestinal Agents therapeutic use, Humans, Immunocompromised Host, Immunosuppressive Agents therapeutic use, Inflammatory Bowel Diseases drug therapy, Inflammatory Bowel Diseases epidemiology, Inflammatory Bowel Diseases immunology, Male, Opportunistic Infections diagnosis, Opportunistic Infections drug therapy, Opportunistic Infections epidemiology, Opportunistic Infections immunology, Prevalence, Recurrence, Retrospective Studies, Treatment Outcome, Cytomegalovirus Infections complications, Inflammatory Bowel Diseases complications, Opportunistic Infections complications
- Abstract
Background: Patients with inflammatory bowel disease (IBD) show an increased risk of developing cytomegalovirus (CMV) disease because of immunosuppressive medication and malnutrition. Here, we aimed to investigate the prevalence and clinical characteristics of CMV disease in our cohort of IBD patients., Patients and Methods: We carried out a retrospective analysis of 1023 IBD patients treated at our IBD clinic at the University Hospital Zurich between 2007 and 2014. CMV disease was defined as a positive immunohistochemistry for CMV and 14 patients were identified., Results: The prevalence of CMV disease in our IBD cohort was 1.37%. Twelve patients had ulcerative colitis and two had Crohn's disease with colonic involvement. All patients who developed CMV disease received immunosuppressive medication or, as in one case, had HIV infection. The most used immunosuppressive medications were steroids and azathioprine. The most common therapeutic strategy was the consecutive use of ganciclovir and valganciclovir. Ten patients recovered and two were treatment refractory; among these, one required colectomy and two had a relapse., Conclusion: CMV disease may influence the clinical course of IBD. There is probably an association between CMV disease and IBD-specific medication. Risk factors, epidemiology and therapeutic strategy need to be further investigated.
- Published
- 2016
- Full Text
- View/download PDF
38. Genotype-Phenotype Associations of the CD-Associated Single Nucleotide Polymorphism within the Gene Locus Encoding Protein Tyrosine Phosphatase Non-Receptor Type 22 in Patients of the Swiss IBD Cohort.
- Author
-
Spalinger MR, Zeitz J, Biedermann L, Rossel JB, Sulz MC, Frei P, Scharl S, Vavricka SR, Fried M, Rogler G, and Scharl M
- Subjects
- Adult, Case-Control Studies, Cohort Studies, Female, Genetic Predisposition to Disease, Humans, Male, Polymorphism, Single Nucleotide, Switzerland, Young Adult, Crohn Disease genetics, Genotype, Inflammatory Bowel Diseases genetics, Phenotype, Protein Tyrosine Phosphatase, Non-Receptor Type 22 genetics
- Abstract
Background: Protein tyrosine phosphatase non-receptor type 22 (PTPN22) plays an important role in immune cell function and intestinal homeostasis. The single nucleotide polymorphism (SNP) rs2476601 within the PTPN22 gene locus results in aberrant function of PTPN22 protein and protects from Crohn's disease (CD). Here, we investigated associations of PTPN22 SNP rs2476601 in inflammatory bowel disease (IBD) patients in the Swiss IBD Cohort Study (SIBDCS)., Methods: 2'028 SIBDCS patients (1173 CD and 855 ulcerative colitis (UC) patients) were included. The clinical characteristics were analysed for an association with the presence of the PTPN22 SNP rs2476601 genotypes 'homozygous variant' (AA), 'heterozygous' (GA) and 'homozygous wild-type' (GG)., Results: 13 patients (0.6%) were homozygous variant (AA) for the PTPN22 polymorphism, 269 (13.3%) heterozygous variant (GA) and 1'746 (86.1%) homozygous wild-type (GG). In CD, AA and GA genotypes were associated with less use of steroids and antibiotics, and reduced prevalence of vitamin D and calcium deficiency. In UC the AA and GA genotype was associated with increased use of azathioprine and anti-TNF antibodies, but significantly less patients with the PTPN22 variant featured malabsorption syndrome (p = 0.026)., Conclusion: Our study for the first time addressed how presence of SNP rs2476601 within the PTPN22 gene affects clinical characteristics in IBD-patients. Several factors that correlate with more severe disease were found to be less common in CD patients carrying the A-allele, pointing towards a protective role for this variant in affected CD patients. In UC patients however, we found the opposite trend, suggesting a disease-promoting effect of the A-allele.
- Published
- 2016
- Full Text
- View/download PDF
39. Association of extraintestinal manifestations and anaemia with disease outcomes in patients with inflammatory bowel disease.
- Author
-
Vegh Z, Kurti Z, Gonczi L, Golovics PA, Lovasz BD, Szita I, Balogh M, Pandur T, Vavricka SR, Rogler G, Lakatos L, and Lakatos PL
- Subjects
- Adult, Anemia complications, Azathioprine therapeutic use, Colitis, Ulcerative complications, Crohn Disease complications, Female, Humans, Inflammatory Bowel Diseases drug therapy, Male, Middle Aged, Severity of Illness Index, Steroids therapeutic use, Young Adult, Inflammatory Bowel Diseases complications
- Abstract
Objective: The association between extraintestinal manifestations (EIMs) and disease activity suggest a common pathogenetic link with inflammatory bowel disease (IBD). We report on the association of EIMs and anaemia with long-term disease outcomes, including treatment steps, hospitalization, and surgery in the prospective population-based IBD inception cohort from Veszprem province., Methods: Data of 678 incident IBD patients (Crohn's disease/ulcerative colitis(CD/UC): 331/347) diagnosed from 1st January 2000 to 31st December 2012 were analyzed (CD: m/f: 176/155, median age at diagnosis: 28, IQR: 21-40 years, disease duration: 6, IQR: 2-9 years; UC: m/f: 200/147, median age at diagnosis: 36, IQR: 26-50 years, duration: 7, IQR: 4-10 years)., Results: EIMs were present in 30% of the CD and 17.3% of the UC patients. In CD, female gender (p = 0.02) need for steroid (p < 0.001) and azathioprine (AZA) (p = 0.02), while in UC, young age at onset (p = 0.03), extensive disease (p = 0.003), female gender (p = 0.07), need for steroids (p < 0.001) and AZA (p = 0.004) and need for IBD-related hospitalization (p = 0.01) were associated with the presence of EIMs. Anaemia was present in 56.7% of the CD and 30.2% of the UC patients. In both CD and UC anaemia was associated with age at onset (pCD = 0.001, pUC = 0.04), disease location/extent (pCD = 0.02, pUC < 0.001), steroid and AZA use (for both pCD,UC < 0.001), need for surgery/colectomy (pCD < 0.001, pUC = 0.002) and hospitalization (pCD = 0.004, pUC < 0.001) and in CD, it was associated with anti TNF therapy(p = 0.002)., Conclusions: The presence of EIMs was associated with disease phenotype in UC and with treatment strategy in both CD and UC. Additionally, anaemia was associated with hospitalization and surgery in both CD and UC, suggesting that EIMs and anaemia may be helpful in stratifying disease severity in IBD.
- Published
- 2016
- Full Text
- View/download PDF
40. The Impact of Azathioprine-Associated Lymphopenia on the Onset of Opportunistic Infections in Patients with Inflammatory Bowel Disease.
- Author
-
Vögelin M, Biedermann L, Frei P, Vavricka SR, Scharl S, Zeitz J, Sulz MC, Fried M, Rogler G, and Scharl M
- Subjects
- Adolescent, Adult, Azathioprine therapeutic use, Case-Control Studies, Child, Female, Humans, Immunosuppressive Agents therapeutic use, Incidence, Male, Middle Aged, Opportunistic Infections chemically induced, Retrospective Studies, Risk Factors, Young Adult, Azathioprine adverse effects, Immunosuppressive Agents adverse effects, Inflammatory Bowel Diseases drug therapy, Inflammatory Bowel Diseases epidemiology, Lymphopenia chemically induced, Lymphopenia epidemiology, Opportunistic Infections epidemiology
- Abstract
Background: Thiopurines are known to cause lymphopenia (<1,500 lymphocytes/μl). As severe lymphopenia (<500C/μl) is associated with opportunistic infections, we investigated severity of thiopurine-related lymphopenia and development of opportunistic infections in our tertiary referral centre., Methods: We retrospectively screened medical records of 1,070 IBD patients and identified 100 individuals that developed a total of 161 episodes of lymphopenia during thiopurine treatment between 2002 and 2014. Occurrence of opportunistic infections was documented. A control group consisted of IBD patients receiving thiopurines but without developing lymphopenia., Results: Of a total of 161 episodes of lymphopenia, 23% were severe (<500C/μl). In this subgroup, thiopurine dosing was modified in 64% (dosage reduction: 32%, medication discontinued: 32%). We identified 9 cases (5.5%) of opportunistic infections, of which only two occurred during severe lymphopenia. One opportunistic infection (4.5%) was identified in the control group. No association was found between opportunistic infections and severity of lymphopenia. All patients who suffered from opportunistic infections were receiving additional immunosuppressive medication., Conclusion: Our patients treated with thiopurines rarely developed severe lymphopenia and opportunistic infections did not occur more often than in the control group. A careful monitoring of lymphocytes and prophylactic adjustment of thiopurine therapy might contribute to this low incidence.
- Published
- 2016
- Full Text
- View/download PDF
41. The First European Evidence-based Consensus on Extra-intestinal Manifestations in Inflammatory Bowel Disease.
- Author
-
Harbord M, Annese V, Vavricka SR, Allez M, Barreiro-de Acosta M, Boberg KM, Burisch J, De Vos M, De Vries AM, Dick AD, Juillerat P, Karlsen TH, Koutroubakis I, Lakatos PL, Orchard T, Papay P, Raine T, Reinshagen M, Thaci D, Tilg H, and Carbonnel F
- Subjects
- Arthritis diagnosis, Arthritis etiology, Arthritis therapy, Cardiovascular Diseases diagnosis, Cardiovascular Diseases etiology, Cardiovascular Diseases therapy, Cholangitis, Sclerosing diagnosis, Cholangitis, Sclerosing etiology, Cholangitis, Sclerosing therapy, Eye Diseases diagnosis, Eye Diseases etiology, Eye Diseases therapy, Female, Female Urogenital Diseases diagnosis, Female Urogenital Diseases etiology, Female Urogenital Diseases therapy, Humans, Liver Diseases diagnosis, Liver Diseases etiology, Liver Diseases therapy, Lung Diseases diagnosis, Lung Diseases etiology, Lung Diseases therapy, Male, Male Urogenital Diseases diagnosis, Male Urogenital Diseases etiology, Male Urogenital Diseases therapy, Nervous System Diseases diagnosis, Nervous System Diseases etiology, Nervous System Diseases therapy, Osteoporosis diagnosis, Osteoporosis etiology, Osteoporosis therapy, Otorhinolaryngologic Diseases diagnosis, Otorhinolaryngologic Diseases etiology, Otorhinolaryngologic Diseases therapy, Pancreatitis diagnosis, Pancreatitis etiology, Pancreatitis therapy, Skin Diseases diagnosis, Skin Diseases etiology, Skin Diseases therapy, Inflammatory Bowel Diseases complications
- Published
- 2016
- Full Text
- View/download PDF
42. The Clinical Relevance of the IBD-Associated Variation within the Risk Gene Locus Encoding Protein Tyrosine Phosphatase Non-Receptor Type 2 in Patients of the Swiss IBD Cohort.
- Author
-
Spalinger MR, Voegelin M, Biedermann L, Zeitz J, Rossel JB, Sulz MC, Frei P, Scharl S, Vavricka SR, Fried M, Rogler G, and Scharl M
- Subjects
- Adalimumab therapeutic use, Adolescent, Adult, Aged, Aged, 80 and over, Certolizumab Pegol therapeutic use, Child, Child, Preschool, Female, Gastrointestinal Agents therapeutic use, Genotype, Humans, Infant, Inflammatory Bowel Diseases epidemiology, Infliximab therapeutic use, Male, Middle Aged, Polymorphism, Single Nucleotide, Prospective Studies, Risk Factors, Switzerland epidemiology, Young Adult, Genetic Predisposition to Disease genetics, Inflammatory Bowel Diseases genetics, Inflammatory Bowel Diseases therapy, Protein Tyrosine Phosphatase, Non-Receptor Type 2 genetics, Tumor Necrosis Factor-alpha antagonists & inhibitors
- Abstract
Background/aims: The single nucleotide polymorphism (SNP) rs1893217 within the gene locus encoding protein tyrosine phosphatase non-receptor type 2 (PTPN2) results in a dysfunctional PTPN2 protein is associated with Crohn's disease (CD) and exists in perfect linkage disequilibrium with the CD- and ulcerative colitis (UC)-associated PTPN2 SNP rs2542151. We investigated associations of PTPN2 SNP rs1893217 and clinical characteristics of inflammatory bowel disease (IBD) patients., Methods: One thousand seventy three patients with CD and 734 patients with UC from the Swiss IBD Cohort Study (SIBDCS) were included. Epidemiologic, disease and treatment characteristics were analysed for an association with the presence of one of the rs1893217 genotypes 'homozygous wild-type' (TT), 'heterozygous' (CT) and 'homozygous variant' (CC)., Results: About 2.88% of IBD patients were identified with CC, 26.8% with CT and 70.4% with TT genotype. The CC-genotype was associated with the existence of gallstones in CD and pancolitis in UC patients. The presence of the C-allele (i.e. either CC or CT genotype) was associated with the onset of uveitis, but protected from aphthous oral ulcers in CD patients. UC patients carrying a C-allele were diagnosed at an older age but required intestinal surgery more often. The presence of the C-allele was associated with a successful treatment with anti-TNF antibodies in both CD and UC patients., Conclusion: IBD patients carrying the C-allele of PTPN2 SNP rs1893217 are at greater risk for developing a severe disease course but are more likely to respond to treatment with anti-TNF antibodies. These findings demonstrate a clinical relevance of this PTPN2 risk variant in IBD patients., (© 2016 S. Karger AG, Basel.)
- Published
- 2016
- Full Text
- View/download PDF
43. High Altitude Journeys, Flights and Hypoxia: Any Role for Disease Flares in IBD Patients?
- Author
-
Vavricka SR, Rogler G, and Biedermann L
- Subjects
- Humans, Aircraft, Altitude, Hypoxia complications, Inflammatory Bowel Diseases etiology, Travel
- Abstract
The importance of environmental factors in the pathogenesis including their disease-modifying potential are increasingly recognized in inflammatory bowel disease (IBD) patients, largely driven by the perception that the prevalence and incidence of IBD are on the rise within the last few years, especially in non-western countries. One of those factors is believed to be hypoxia. The role of hypoxia as a modifying or even causative factor in the genesis and maintenance of inflammation has been increasingly elucidated in recent years. Hypoxia is believed to be a main inducing factor of inflammation. This has been studied in different animal experiments as well as in humans exposed to hypoxia. In several studies - mainly in mice - animals exposed to short-term hypoxia accumulated inflammatory cells in multiple organs and showed elevated cytokines in the blood. Comparable studies were performed in humans, mainly in healthy mountaineers. Recently, we reported on the association between IBD flare-up episodes and antecedent journeys to high-altitude region and aircraft travels. According to these findings, we concluded that flights and stays at high altitudes of >2,000 mg are a risk factor for increased disease activity in IBD. To evaluate the potential influence of hypoxia on the course of IBD on a biomolecular level and to test the effects of hypoxia under standardized conditions, we initiated a prospective and controlled investigation in both healthy controls and IBD patients in stable remission. The study participants underwent a 3-hour exposure to hypoxic conditions simulating an altitude of 4,000 m above sea level in a hyperbaric pressure chamber and clinical parameters as well as blood and stool samples were collected at several time points. The first results of this study are expected in the near future., (© 2016 S. Karger AG, Basel.)
- Published
- 2016
- Full Text
- View/download PDF
44. Malignancies in Patients with Inflammatory Bowel Disease: A Single-Centre Experience.
- Author
-
Madanchi M, Zeitz J, Barthel C, Samaras P, Scharl S, Sulz MC, Biedermann L, Frei P, Vavricka SR, Rogler G, and Scharl M
- Subjects
- Adult, Aged, Aged, 80 and over, Bile Duct Neoplasms etiology, Carcinoma, Transitional Cell etiology, Cholangiocarcinoma etiology, Colorectal Neoplasms etiology, Female, Humans, Immunosuppressive Agents adverse effects, Immunosuppressive Agents therapeutic use, Incidence, Inflammatory Bowel Diseases complications, Inflammatory Bowel Diseases drug therapy, Lymphoma, Non-Hodgkin etiology, Male, Middle Aged, Prostatic Neoplasms etiology, Retrospective Studies, Risk Factors, Switzerland epidemiology, Urinary Bladder Neoplasms etiology, Young Adult, Bile Duct Neoplasms epidemiology, Carcinoma, Transitional Cell epidemiology, Cholangiocarcinoma epidemiology, Colorectal Neoplasms epidemiology, Inflammatory Bowel Diseases epidemiology, Lymphoma, Non-Hodgkin epidemiology, Prostatic Neoplasms epidemiology, Urinary Bladder Neoplasms epidemiology
- Abstract
Background: Gastrointestinal and extraintestinal malignancies are long-term complications in patients with inflammatory bowel disease (IBD), likely as a result of chronic inflammation and the use of immunosuppressive medications used to control inflammation. Here, we assessed the frequency of malignancies in a large tertiary IBD centre at the University Hospital Zurich., Methods: We performed a retrospective analysis of data from 1,026 patients from our IBD clinic treated between 2007 and 2014., Results: Twenty two of the 1,026 patients developed 28 cases of malignancies, 14 patients were male and 8 patients female. The median latency between IBD diagnosis and first malignancy was 13 years (range 2-27 years). Most common malignancies were non-Hodgkin lymphoma, colorectal cancer (CRC), urothelial carcinoma, cholangiocellular carcinoma (CCC) and prostate cancer. The most common tumour type in Crohn's disease patients (13/22) was lymphoma (5 cases), in ulcerative colitis patients (9/22) CCC (2 cases) and CRC (2 cases). The observed incidence of lymphoma (32.5/100,000), bladder carcinoma (21.7/100,000) and CCC (10.8/100,000) was higher than expected and known from general population. All of the patients that developed a malignancy had received immunosuppressive therapy. Compared to a cohort of 927 IBD patients without malignancies there were no statistical differences regarding gender, antibodies targeting tumour necrosis factor and thiopurine use., Conclusion: Our data support the assumption that a long-standing disease course and immunosuppressive therapy increase the risk for developing malignancies in IBD patients., (© 2016 S. Karger AG, Basel.)
- Published
- 2016
- Full Text
- View/download PDF
45. Patients' perceptions on the impact of coffee consumption in inflammatory bowel disease: friend or foe?--a patient survey.
- Author
-
Barthel C, Wiegand S, Scharl S, Scharl M, Frei P, Vavricka SR, Fried M, Sulz MC, Wiegand N, Rogler G, and Biedermann L
- Subjects
- Colitis, Ulcerative pathology, Crohn Disease pathology, Feeding Behavior, Humans, Intestines pathology, Surveys and Questionnaires, Switzerland, Coffee adverse effects, Health Knowledge, Attitudes, Practice, Inflammatory Bowel Diseases pathology
- Abstract
Background: Environmental factors are an integral component in the pathogenesis of inflammatory bowel disease (IBD). There is an increasing interest in nutritive components. While the potential disease-modifying role of coffee has been intensively investigated in a variety of gastrointestinal diseases, the data on the potential impact on IBD is very limited. We aimed to determine the patients' perspective on coffee consumption in IBD., Methods: We conducted a questionnaire among IBD patients in Switzerland, assessing key questions regarding coffee consumption. Descriptive statistics including chi square testing were used for analysis of questionnaire data., Results: Among a total of 442 patients 73% regularly consume coffee. 96% of patients attributing a positive and 91% of patients attributing no impact of coffee intake on IBD regularly drink coffee and surprisingly even 49% of those patients that assign a negative impact on disease symptoms. Among those patients refraining from regular coffee intake 62% are convinced that coffee adversely influences intestinal symptoms, significantly more in Crohn's disease (CD) than in ulcerative colitis (UC) (76% vs. 44%, p = 0.002). In total, 38% of all study subjects suppose that coffee has an effect on their symptoms of disease, significantly more in CD (54%) compared to UC patients (22%, p < 0.001). Moreover, while 45% of CD patients feel that coffee has a detrimental influence, only 20% of UC patients share this impression (p < 0.001)., Conclusion: Two thirds of IBD patients regularly consume coffee. More than twice as many CD compared to UC patients attribute a symptom-modifying effect of coffee consumption, the majority a detrimental one. However, this negative perception does not result in abstinence from coffee consumption.
- Published
- 2015
- Full Text
- View/download PDF
46. Extraintestinal Manifestations of Inflammatory Bowel Disease.
- Author
-
Vavricka SR, Schoepfer A, Scharl M, Lakatos PL, Navarini A, and Rogler G
- Subjects
- Humans, Prognosis, Biliary Tract Diseases etiology, Eye Diseases etiology, Inflammatory Bowel Diseases complications, Liver Diseases etiology, Musculoskeletal Diseases etiology, Skin Diseases etiology
- Abstract
Extraintestinal manifestations (EIM) in inflammatory bowel disease (IBD) are frequent and may occur before or after IBD diagnosis. EIM may impact the quality of life for patients with IBD significantly requiring specific treatment depending on the affected organ(s). They most frequently affect joints, skin, or eyes, but can also less frequently involve other organs such as liver, lungs, or pancreas. Certain EIM, such as peripheral arthritis, oral aphthous ulcers, episcleritis, or erythema nodosum, are frequently associated with active intestinal inflammation and usually improve by treatment of the intestinal activity. Other EIM, such as uveitis or ankylosing spondylitis, usually occur independent of intestinal inflammatory activity. For other not so rare EIM, such as pyoderma gangrenosum and primary sclerosing cholangitis, the association with the activity of the underlying IBD is unclear. Successful therapy of EIM is essential for improving quality of life of patients with IBD. Besides other options, tumor necrosis factor antibody therapy is an important therapy for EIM in patients with IBD.
- Published
- 2015
- Full Text
- View/download PDF
47. Chronological Order of Appearance of Extraintestinal Manifestations Relative to the Time of IBD Diagnosis in the Swiss Inflammatory Bowel Disease Cohort.
- Author
-
Vavricka SR, Rogler G, Gantenbein C, Spoerri M, Prinz Vavricka M, Navarini AA, French LE, Safroneeva E, Fournier N, Straumann A, Froehlich F, Fried M, Michetti P, Seibold F, Lakatos PL, Peyrin-Biroulet L, and Schoepfer AM
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Arthritis etiology, Cohort Studies, Erythema Nodosum etiology, Female, Follow-Up Studies, Humans, Male, Middle Aged, Prognosis, Pyoderma Gangrenosum etiology, Spondylitis, Ankylosing etiology, Stomatitis, Aphthous etiology, Switzerland, Time Factors, Young Adult, Arthritis diagnosis, Erythema Nodosum diagnosis, Inflammatory Bowel Diseases complications, Pyoderma Gangrenosum diagnosis, Spondylitis, Ankylosing diagnosis, Stomatitis, Aphthous diagnosis
- Abstract
Background: Data evaluating the chronological order of appearance of extraintestinal manifestations (EIMs) relative to the time of inflammatory bowel disease (IBD) diagnosis is currently lacking. We aimed to assess the type, frequency, and chronological order of appearance of EIMs in patients with IBD., Methods: Data from the Swiss Inflammatory Bowel Disease Cohort Study were analyzed., Results: The data on 1249 patients were analyzed (49.8% female, median age: 40 [interquartile range, 30-51 yr], 735 [58.8%] with Crohn's disease, 483 [38.7%] with ulcerative colitis, and 31 [2.5%] with indeterminate colitis). A total of 366 patients presented with EIMs (29.3%). Of those, 63.4% presented with 1, 26.5% with 2, 4.9% with 3, 2.5% with 4, and 2.7% with 5 EIMs during their lifetime. Patients presented with the following diseases as first EIMs: peripheral arthritis 70.0%, aphthous stomatitis 21.6%, axial arthropathy/ankylosing spondylitis 16.4%, uveitis 13.7%, erythema nodosum 12.6%, primary sclerosing cholangitis 6.6%, pyoderma gangrenosum 4.9%, and psoriasis 2.7%. In 25.8% of cases, patients presented with their first EIM before IBD was diagnosed (median time 5 mo before IBD diagnosis: range, 0-25 mo), and in 74.2% of cases, the first EIM manifested itself after IBD diagnosis (median: 92 mo; range, 29-183 mo)., Conclusions: In one quarter of patients with IBD, EIMs appeared before the time of IBD diagnosis. Occurrence of EIMs should prompt physicians to look for potential underlying IBD.
- Published
- 2015
- Full Text
- View/download PDF
48. Prevalence of anemia in inflammatory bowel diseases in european countries: a systematic review and individual patient data meta-analysis.
- Author
-
Filmann N, Rey J, Schneeweiss S, Ardizzone S, Bager P, Bergamaschi G, Koutroubakis I, Lindgren S, Morena Fde L, Moum B, Vavricka SR, Schröder O, Herrmann E, and Blumenstein I
- Subjects
- Anemia etiology, Europe epidemiology, Humans, Prevalence, Prognosis, Anemia epidemiology, Inflammatory Bowel Diseases complications
- Abstract
Background: The main objective is to determine the overall prevalence of anemia in inflammatory bowel diseases (IBD) in Europe., Methods: A systematic literature search in PubMed and Embase was performed for studies published between January 2007 and May 2012. Eligible studies were included if they were original full-paper publications originated from Europe and if the authors agreed to provide their data. An overall prevalence of anemia in IBD, disease specific, and age-gender stratified basis prevalences were estimated. The influence of disease entity (Crohn's disease/ulcerative colitis), gender, age, disease activity (remission/active disease), and IBD-specific treatment strategies on the prevalence of anemia was analyzed by a mixed logistic regression model. Thereby, the factor country of origin was included as a random effect., Results: Data were available for 2192 patients, mainly treated in tertiary referral centers. The overall prevalence of anemia in IBD patients was 24% (95% confidence interval, 18-31). Age-gender stratified prevalences were estimated for the age strata 18 to 29, 30 to 39, 40 to 49, 50 to 64, 65 to 74, >74 years and ranged from 18% to 35%. Patients receiving IBD-specific medication (P = 0.0002, odds ratio 1.54), and patients with active disease status (P < 0.0001, odds ratio 2.72) were significantly more likely to have anemia compared with patients not receiving IBD-specific medication or being in remission. Patients with ulcerative colitis tended to have anemia less likely than patients with Crohn's disease (P = 0.01, odds ratio 0.77)., Conclusions: The overall prevalence of anemia in patients with Crohn's disease was 27% (95% confidence interval, 19-35) and 21% (95% confidence interval, 15-27) in patients with ulcerative colitis. Thereby, 57% of the anemic patients were iron deficient.
- Published
- 2014
- Full Text
- View/download PDF
49. Biologics for extraintestinal manifestations of IBD.
- Author
-
Vavricka SR, Scharl M, Gubler M, and Rogler G
- Subjects
- Clinical Trials as Topic, Eye Diseases drug therapy, Humans, Inflammatory Bowel Diseases pathology, Liver Diseases drug therapy, Musculoskeletal Diseases drug therapy, Quality of Life, Skin Diseases drug therapy, Tumor Necrosis Factor-alpha antagonists & inhibitors, Antibodies, Monoclonal therapeutic use, Biological Products therapeutic use, Inflammatory Bowel Diseases complications, Inflammatory Bowel Diseases drug therapy
- Abstract
Extraintestinal manifestations (EIM) in inflammatory bowel disease (IBD) occur frequently and may present themselves before or after IBD diagnosis. They most commonly affect the eyes, skin, and joints, but can also involve other organs such as the liver. Some EIM are associated with intestinal disease activity and ameliorate by treatment of the underlying IBD. This is seen in patients with peripheral Type 1 arthritis, oral aphthous ulcers, episcleritis, and erythema nodosum. Other EIM are intestinal disease activity-independent such as uveitis, and ankylosing spondylitis. Finally, some EIM (e.g. pyoderma gangrenosum and primary sclerosing cholangitis) may or may not be associated with the underlying IBD. Successful therapy of EIM is important for improving quality of life of IBD patients. TNF antibody therapy is an important treatment option for EIM in IBD patients whereas no such beneficial effect was reported for alpha 4 beta 7 integrin antibodies such as vedolizumab so far. This article reviews the therapeutic experience with TNF antibodies for the treatment of EIM in IBD patients.
- Published
- 2014
- Full Text
- View/download PDF
50. Review: new anti-cytokines for IBD: what is in the pipeline?
- Author
-
Scharl M, Vavricka SR, and Rogler G
- Subjects
- Antibodies therapeutic use, Clinical Trials as Topic, Databases, Factual, Humans, Immunologic Factors therapeutic use, Inflammatory Bowel Diseases pathology, Signal Transduction drug effects, Signal Transduction genetics, Cytokines antagonists & inhibitors, Inflammatory Bowel Diseases drug therapy, Molecular Targeted Therapy
- Abstract
Significant advances have been achieved in the understanding of the pathogenesis of inflammatory bowel disease (IBD). A number of susceptibility genes have been detected by large genome wide screening-approaches. New therapeutic concepts emerge from these insights. The most important progress in recent years certainly is the introduction of biologics in the therapy of IBD. TNF blockers have been shown to be very effective for the control of complicated disease courses. Currently, in addition to the three already established anti-TNF antibodies, new anti-TNF molecules, for example Golimumab, are in clinical trials and also reveal promising results. However, not all of the patients respond to anti-TNF treatment and many patients lose their response. Therefore, additional therapeutic approaches are urgently needed. Attractive therapy targets are cytokines as well as their receptors and signaling pathways. At the moment a large number of biologicals and inhibitors are tested in clinical trials and some of them provide very promising results for the treatment of IBD patients. In particular, inhibition of IL-12p40 by specific antibodies as well as of the janus kinase (JAK)3 by a small molecule promise to be very effective approaches. Though antibodies targeting for example IL-6, IL-6R, IL-13 or CCR9 are only in the early steps of clinical development, they have already demonstrated to be a possible treatment option which needs to be confirmed in further trials. Taken together a large number of new therapeutic anti-cytokine approaches are currently tested in clinical trials in IBD patients. In this review, the new therapeutic approaches for cytokine inhibition in IBD patients are discussed.
- Published
- 2013
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.